Clinical Trial Update: A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection [Phase 2]

View source ↗

Summary

Phase II randomized study evaluating exosomes overexpressing CD24 to prevent deterioration in moderate to severe COVID-19 patients; status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Disease

Drugs mentioned

• Exosomes Overexpressing CD24

Snippet

Sponsor: Eli Sprecher, MD | Conditions: COVID-19 Disease | Phase 2 | Status: UNKNOWN